Shionogi Inc. (U.S.)

Recently, NEJM Group published results from a Phase 3 study evaluating our investigational oral antiviral for the prevention of COVID-19 following exposure to an infected individual. Aeron Hurt, PhD, our Vice President, Global Medical Science, shares his thoughts about these findings. #InfectiousDisease #COVID19 Learn more: https://lnkd.in/eXmim47Z

#BREAKINGNEWS: Results from our SCORPIO-PEP clinical trial, the first and only Phase 3 study of an investigational oral antiviral to meet the primary endpoint of preventing symptomatic COVID-19 following exposure to an infected individual have been published in The New England Journal of Medicine (NEJM Group). #InfectiousDisease #COVID19 Learn more: https://lnkd.in/eXmim47Z

Antibiotics are a cornerstone of modern medicine, essential for treating common infections and ensuring that medical procedures and surgeries are safe. But antibiotic innovation has not kept pace with the rise of antibiotic-resistant infections. In a new Nature Magazine supplement focused on antimicrobial resistance (AMR), Gareth Morgan examines why antibiotic innovation is increasingly challenging and highlights the emerging economic and policy solutions, including push and pull incentives, that can help support the development of new antibiotics. Along with our subsidiary Qpex Biopharma, Inc., we are among the few companies continuing to develop treatments to address current and future infectious disease threats. Approaches like these are critical to sustaining innovation in the field and ensuring patients retain access to effective treatments. Read the article to learn more: https://lnkd.in/gB_EVmaY

New this year, the Society of Infectious Diseases Pharmacists (SIDP) is co-hosting the MAD-ID: Making a Difference in Infectious Diseases annual meeting #MADID2026 and we're excited to meet with emerging leaders and established experts who are making a difference in infectious diseases. This inaugural event will bring the latest in scientific innovation and real-world research together to create the dynamic cross-functional engagement that infectious disease requires today. From plenaries to classroom sessions to the exhibit floor, there will be a broad range of learning opportunities on everything from antimicrobials to microbiology to stewardship. Don't miss our sponsored talk with Jason Gallagher, PharmD, FCCP on May 16 from 9:30 - 10:30 a.m. EDT. Dr. Gallagher will highlight data on our antibiotic for serious Gram-negative bacterial infections in adult patients across in vitro, clinical, and real-world settings. We'll see you in Orlando. Find us at booth #206.

#News: Our parent company Shionogi & Co., Ltd. has joined the World Economic Forum and signed the Davos Compact on Antimicrobial Resistance (AMR), a collective commitment to address the rising global health threat resulting from reduced response to available treatments. Along with our colleagues at Qpex Biopharma, Inc., we're working to advance sustainable and effective solutions to address AMR through international collaboration, public-private partnerships, research & development, responsible manufacturing and global surveillance of problematic and emerging pathogens. Learn more here: https://lnkd.in/eAAQg6YZ

Our efforts to address antimicrobial resistance (AMR) have been recognized by Access to Medicine Foundation and, for the first time, Shionogi & Co., Ltd. is ranked 2nd among large R&D companies in the Antimicrobial Resistance Benchmark Report. #AMRB26 This recognition reflects the impact of our commitment to research new drugs, responsibly manufacture existing medicines, improve access and advance stewardship initiatives. Our work to discover and develop novel anti-infectives began in the 1950s and, along with our subsidiary Qpex Biopharma, Inc. and our diverse network of collaborators and research partners, we'll continue innovating for years to come. At a time when antibiotic resistance is increasing, sustained and decisive leadership in antibiotic innovation has never been more urgent. Find out more about our work and this report: https://lnkd.in/dfq9dWGW

As we continue to grow, so does our annual Take Your Child to Work Day. This year, we welcomed more than 80 children to our New Jersey headquarters for a day of hands-on learning about our business, values, and Japanese heritage. From science experiments and pharma-themed “Family Feud” to a celebration of Japan’s Sports Day, there was something for everyone. The event was especially meaningful as new teammates from our recent ALS treatment acquisition—and their children—experienced Shionogi’s culture firsthand. Thank you to the volunteers who made this our best Take Your Child to Work Day yet. Casey Justice, Yamibel F., Shawnakay Grant, Courtney Messina, Cali Brantner, Shetal Shanbhag, Risa Sho, Omar Richardson, Stacey Levine, Michael Borowik, Srivani Vaidhyanathan, Lindsay Macrino, Brian Madgey, Catherine Vo Handwerger, KRISHNA RANA, Shouko Kan-o, Yuko Iwasaki, Yoshihiro Akiyama, Elissa Santo, Deviyani Mercado, Asako Sakae, Reshma Verma, Niti Sawhney, Hilary Garzarelli, MBA, PMP

At #ESCMID26, we are presenting a post hoc analysis from three Phase 3 trials exploring the antiviral activity of our investigational COVID-19 antiviral currently under review by the FDA. Key measures of antiviral activity include the ability to reduce both levels of viral RNA (viral load), and importantly, the amount of infectious virus determined by viral culture. COVID-19 remains a public health challenge. A COVID-19 infection can become severe, and even if mild or moderate, it can exacerbate or worsen chronic conditions or lead to the onset of new ones, including long COVID. There is a need for new approaches to managing COVID-19, including novel methods of prevention.

This year at #ESCMID26, we're sharing an oral presentation highlighting Phase 2 results from a study on our novel investigational oral antiviral candidate for the treatment of COVID-19. COVID-19 continues to be associated with substantial clinical risk and impact to patients' health, particularly in vulnerable populations. Building on our legacy in antiviral expertise, we're advancing options to treat and prevent COVID-19.

United by the message that "Together We Are Strong," Shionogi recognizes #InternationalPompeDay on April 15th. We are committed to raising global awareness of #PompeDisease and amplifying initiatives to aid early diagnosis through efforts like newborn screening. A heartfelt thank you to all the families, caregivers, healthcare workers and patient advocacy groups who are dedicated to making a difference in Pompe disease. Your strength inspires us all. #TogetherWeAreStrong #PompeDisease #PatientAdvocacy